（编辑 王雪儿） 证券日报网讯 爱尔眼科8月25日在互动平台回答投资者提问时表示，公司近年有条不紊持续推进高质量 发展战略，资金使用将动态评估发展需要并合理规划。公司已完成两期股票回购，后续如有进一步回购 计划，将按照相关规则披露。 ...

证券代码：300015 股票简称：爱尔眼科 公告编号：2025-058 （一）本次注销的部分募集资金专项账户基本情况 | 开户银行 | 银行账号 | 存续状态 | | --- | --- | --- | | 北京银行股份有限公司长沙伍家岭支行 | 20000017923500099405237 | 注 销 | （二）本次部分募集资金专项账户注销情况 爱尔眼科医院集团股份有限公司 关于部分募集资金专户销户完成的公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意爱尔眼科医院集团股份有限公司向特定 对象发行股票注册的批复》（证监许可[2022]1704 号）同意注册，公司向特定对象 发行人民币普通股股票（A 股）133,467,485 股，每股面值人民币 1.00 元，发行价 格为 26.49 元/股，募集资金总额为人民币 3,535,553,677.65 元，扣除含税的发行 费用人民币 24,311,497.54 元，实际募集资金净额为人民币 3,511,242,180.11 元。 本次发行募集资金已于 2 ...

Core Viewpoint - The medical sector is experiencing significant activity, with the largest medical ETF in A-shares (512170) showing a 2% increase, nearing last year's peak, indicating strong investor confidence in the medical market [1][3]. Group 1: ETF Performance - The medical ETF (512170) reached a peak increase of 2%, with a trading volume exceeding 700 million yuan on the morning of August 25 [1]. - The latest scale of the ETF is 27.94 billion yuan, maintaining a leading position among similar ETFs [1]. - On the previous trading day, the ETF saw a net subscription of 98.54 million yuan, reflecting positive market sentiment towards the medical sector [1]. Group 2: Market Dynamics - Major stocks within the ETF, such as Meihua Medical and Lepu Medical, surged over 15%, while Wu Electric Physiology and other companies experienced declines [1][3]. - The ETF passively tracks the CSI Medical Index, with top-weighted stocks including Mindray Medical, United Imaging Healthcare, and Aier Eye Hospital [3]. Group 3: Policy and Innovation - The National Medical Products Administration announced support for companies to conduct global clinical trials simultaneously, aiming to shorten the drug approval process [3]. - A recent investment cooperation exchange meeting in Shenzhen focused on supporting the development of pharmaceuticals and medical devices [4]. - The establishment of a domestic medical technology innovation zone at the Medical Expo highlighted breakthroughs in domestic technology, with companies like Mindray and Weigao showcasing advanced diagnostic equipment [5]. Group 4: Industry Outlook - CITIC Securities noted that the performance and valuation of the medical device sector are gradually recovering, with recent procurement policies being optimized [5]. - The medical device industry is expected to benefit from policy easing, procurement clearance, and strategic transformations, with internationalization, technological innovation, and mergers and acquisitions becoming key growth paths [5].

Group 1 - Key Point 1: Focus on the release of important economic data including the US July PCE, Q2 GDP, and July durable goods orders, as well as China's August official PMI and July profits of large-scale industrial enterprises [1] - Key Point 2: Companies scheduled to announce earnings include Nvidia, Alibaba, Meituan, Pinduoduo, Luxshare Precision, Newray, and Zhongji Xuchuang [1] - Key Point 3: Additional tariffs imposed by the US on India, bringing the total tariff rate to 50% [1][5] Group 2 - Key Point 1: Earnings announcements on August 25 include Pinduoduo, Haidilao, Luxshare Precision, Poly Development, Hengli Hydraulic, and Newray [2] - Key Point 2: On August 26, key economic indicators such as the US July durable goods orders will be released, along with earnings from companies like China Petroleum and Aier Eye Hospital [3] - Key Point 3: On August 27, the release of China's July profits of large-scale industrial enterprises is anticipated, alongside earnings from companies like Nvidia and Meituan [4] Group 3 - Key Point 1: On August 28, the US will release revised Q2 GDP and PCE data, with earnings announcements from companies like Yili and Mindray [5] - Key Point 2: On August 29, the US July PCE price index will be released, with Alibaba also announcing its earnings [6] - Key Point 3: China's August official manufacturing PMI will be released on August 31 [7]

Core Insights - Aier Eye Hospital in Wuxi has successfully hosted the "Global ICL Surgery Volume Ten Consecutive Championships Expert Meeting," showcasing its expertise in ICL (Implantable Collamer Lens) surgeries and attracting numerous eye care experts and patients [1][10] - Since 2015, Aier Eye Hospital has completed over 550,000 ICL surgeries, maintaining its position as the global leader in this field for ten consecutive years, reflecting both technological advantages and patient trust in the Aier brand [1][8] Group 1: Technology and Expertise - ICL surgery is highlighted for its unique advantages, including non-invasive nature, preservation of the eye's original structure, and reversibility, making it a safer option for patients with high myopia and other complex eye conditions [2][4] - The hospital has established a team of experienced experts who provide personalized surgical plans based on comprehensive pre-operative assessments, ensuring high-quality visual outcomes for patients [4][10] Group 2: Patient Experience and Community Engagement - Patient testimonials during the event emphasized the trust in the hospital's technology and team, with employees sharing their positive experiences as both medical professionals and patients [5][7] - The event also served as a platform for promoting eye health knowledge and community service, with Aier Eye Hospital committed to making advanced myopia correction techniques accessible to more citizens [10] Group 3: Recognition and Future Plans - Aier Eye Hospital received the "Global ICL Surgery Volume First Medical Institution (2015-2025)" certification from STAAR Surgical, acknowledging its leadership and contributions in the ICL field [8][10] - The hospital plans to continue advancing ICL technology alongside other surgical methods, aiming to provide more personalized and safer visual health services for diverse patient populations [10]

Core Viewpoint - The CSI All Share Healthcare Equipment and Services Index has shown significant growth, reflecting a positive trend in the healthcare sector, with a notable increase in trading volume and index performance over various time frames [1][2]. Group 1: Index Performance - The CSI All Share Healthcare Equipment and Services Index rose by 0.14% to 15,554.17 points, with a trading volume of 35.351 billion [1]. - Over the past month, the index has increased by 10.85%, by 14.71% over the last three months, and by 13.47% year-to-date [1]. Group 2: Index Composition - The index comprises companies related to the healthcare theme, with the top ten weighted companies being Mindray Medical (9.17%), United Imaging (7.63%), Aier Eye Hospital (7.12%), and others [1]. - The index is primarily composed of companies listed on the Shenzhen Stock Exchange (59.89%) and the Shanghai Stock Exchange (40.11%) [1]. Group 3: Industry Representation - The index exclusively represents the healthcare sector, with a 100% allocation to pharmaceutical and healthcare-related companies [2]. - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. Group 4: Investment Products - Several public funds track the CSI All Share Healthcare Equipment and Services Index, including various Southern and Tianhong funds, as well as ETFs from different asset management companies [2].

Core Insights - The report emphasizes the focus on the innovative drug industry chain and reasonably valued medical device targets for investment strategies in the pharmaceutical and biotechnology sector [1][4]. Investment Strategy - The investment strategy suggests paying attention to the innovative drug industry chain and reasonably valued medical device targets. The proposed investment portfolio for August 2025 includes A-shares such as Mindray Medical, WuXi AppTec, Aier Eye Hospital, New Industry, Huatai Medical, Kaili Medical, Aohua Endoscopy, Adebiotech, Aibo Medical, and KingMed Diagnostics, as well as H-shares like Kangfang Biologics, Kelun-Botai Biologics-B, Hutchison China MediTech, Kangnuo-B, Sanofi, WuXi AppTec, Aikang Medical, and Gushengtang [4][5]. Market Trends - The National Healthcare Security Administration (NHSA) has released a list of drugs that passed the initial review for innovative drugs, indicating potential growth from commercial insurance. In 2025, the NHSA received 718 submissions for the basic medical insurance directory, with 534 passing the initial review, and 141 submissions for the commercial insurance innovative drug directory, with 121 passing the initial review [4][9]. Clinical Data and Conferences - The report highlights the upcoming World Lung Cancer Conference (WCLC) and European Society for Medical Oncology (ESMO) meetings, where several domestic innovative drugs will present their research results, showcasing the increasing competitiveness of domestic innovative drugs in global markets [4][9]. Policy Changes - The report notes a shift in the centralized procurement policy, moving away from a simple lowest price reference to a more balanced approach that considers clinical stability, quality assurance, and cost justification. This change is expected to improve the profitability of the medical device industry in the coming years [4][9]. Industry Performance - The pharmaceutical industry showed a 13.93% increase in July, outperforming the CSI 300 index by 10.38%. Sub-sectors such as medical services, chemical pharmaceuticals, and biological products experienced significant growth, with increases of 23.10%, 17.92%, and 12.54% respectively [10][12]. Valuation Insights - The overall valuation level of the pharmaceutical and biotechnology sector is currently at a historical percentile of 80.69%, with a price-to-earnings (PE) ratio of 39.11. The sector's premium relative to the CSI 300 and the entire A-share market is at its five-year average [21][22].

Group 1 - The stock price of Aier Eye Hospital closed at 13.24 yuan on August 20, 2025, reflecting a 1.22% increase from the previous trading day, with a trading volume of 1.389 billion yuan and a fluctuation of 2.52% [1] - Aier Eye Hospital is a leading ophthalmology medical chain in China, offering services in refractive surgery, cataract treatment, and vision care [1] - The Shanghai Aier Eye Hospital has introduced a plasma coating care technology that can repair scratched corneal reshaping lenses (OK lenses), effectively reducing the cost for parents to replace lenses. This technology cleans the lens surface using low-temperature argon plasma, achieving a sterilization rate of over 90%, and has already helped over a hundred children extend the lifespan of their lenses in outpatient settings [1] Group 2 - On August 20, Aier Eye Hospital saw a net inflow of 23.5613 million yuan in main funds, while there was a net outflow of 1.79 billion yuan over the past five days [2]

证券代码：300015 股票简称：爱尔眼科 公告编号：2025-057 爱尔眼科医院集团股份有限公司 关于使用部分闲置自有资金进行现金管理的实施公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 3 月 24 日召开第六届董事会第三十二次会议和第六届监事会第二十次会议，审议通过了 《关于使用部分闲置自有资金进行现金管理的议案》，同意公司在保证日常经营 资金需求和资金安全的前提下，使用不超过人民币 15 亿元的闲置自有资金购买 安全性高、流动性好、风险性低的理财产品，期限为自公司第六届董事会第三十 二次会议决议之日起 12 个月。在上述额度及期限内，资金可循环滚动使用，由 公司财务中心负责具体购买事宜。上述内容详见公司 2025 年 3 月 24 日在巨潮资 讯网（www.cninfo.com.cn）披露的相关公告。 根据上述决议，公司全资子公司爱尔眼科国际（香港）有限公司于近期办理 了投资理财业务。现就具体事项公告如下： 一、本次使用部分暂时闲置自有资金进行现金管理的实施情况 产品名称：花旗银行双货 ...

Market Overview - On August 20, the medical services sector rose by 0.33% compared to the previous trading day, with Haocen Medical leading the gains [1] - The Shanghai Composite Index closed at 3766.21, up 1.04%, while the Shenzhen Component Index closed at 11926.74, up 0.89% [1] Top Gainers in Medical Services - Haocen Medical (002622) closed at 3.96, up 10.00% with a trading volume of 827,000 shares and a transaction value of 322 million yuan [1] - Meinian Health (002044) closed at 5.87, up 4.45% with a trading volume of 2,284,200 shares and a transaction value of 1.323 billion yuan [1] - Baicheng Pharmaceutical (301096) closed at 56.47, up 3.31% with a trading volume of 72,900 shares and a transaction value of 401 million yuan [1] Top Losers in Medical Services - Innovation Medical (002173) closed at 23.05, down 7.21% with a trading volume of 1,255,900 shares and a transaction value of 2.968 billion yuan [2] - Boji Pharmaceutical (300404) closed at 12.36, down 6.01% with a trading volume of 819,000 shares and a transaction value of 1.015 billion yuan [2] - Nanmo Biological (688265) closed at 61.50, down 5.38% with a trading volume of 32,800 shares and a transaction value of 201 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 2.075 billion yuan from institutional investors, while retail investors saw a net inflow of 1.893 billion yuan [2][3] - The top net inflow from retail investors was in Meinian Health (002044) with 201 million yuan, despite a net outflow from institutional investors [3] - Haocen Medical (002622) had a net inflow of 114 million yuan from institutional investors, but also faced significant outflows from retail investors [3]